Drug Profile
Grass pollen allergy immunotherapy - Leti Pharma
Alternative Names: Depigoid 34% GrassesMix/33% olea europaea/33% salsola kali; Depigoid Grass Mix; Depigoid Phleum pratense; Depigoid® Phleum; Modified allergen extract of Phleum pratenseLatest Information Update: 22 Aug 2019
Price :
$50
*
At a glance
- Originator Laboratorios LETI; LETI Pharma GmbH
- Class Allergens; Antiallergics; Plant allergy immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Allergic rhinoconjunctivitis; Seasonal allergic rhinitis
Most Recent Events
- 22 Aug 2019 Discontinued - Phase-II for Allergic rhinoconjunctivitis in Poland, Czech Republic, Belgium (SC)
- 22 Aug 2019 Discontinued - Phase-II for Seasonal allergic rhinitis in Belgium, Czech Republic, Poland (SC)
- 22 Aug 2019 Discontinued - Phase-III for Allergic rhinoconjunctivitis in Spain, Hungary (SC)